Monday, November 26, 2018
Orchard Therapeutics initiated at Goldman Sachs
Orchard Therapeutics initiated with a Neutral at Goldman Sachs. Goldman Sachs analyst Graig Suvannavejh started Orchard Therapeutics with a Neutral rating and $18 price target. The prospects of the company’s potential “best-in-class” gene therapy platform are already priced in at current share levels, Suvannavejh tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2827507
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.